Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYL719 monotherapy in advanced breast cancer
ACTRN12615000850572Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpelisib in breast cancer, triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative breast cancer (2 cohorts), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Objective response rate. Started Aug 2015; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)hormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on ACTRN12615000850572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000850572.